How much profit has Medincell made this year?
Medincell has made -25.04 M EUR this year.
Medincell Net Income 2024
Medincell Net Income
-25.04 M EUR
Ticker
MEDCL.PA
ISIN
FR0004065605
WKN
A2N6VA
In 2024, Medincell's profit amounted to -25.04 M EUR, a -21.78% increase from the -32.01 M EUR profit recorded in the previous year.
The Medincell Net Income history
| YEAR | NET INCOME (undefined EUR) |
|---|---|
| 2028e | 74.85 |
| 2027e | 53.86 |
| 2026e | 8.21 |
| 2025e | -8.57 |
| 2024 | -25.04 |
| 2023 | -32.01 |
| 2022 | -24.81 |
| 2021 | -18.99 |
| 2020 | -23.92 |
| 2019 | -19.69 |
| 2018 | -9.57 |
Medincell Revenue, EBIT, Net Income FR0004065605 · A2N6VA
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Medincell, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Medincell from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Medincell’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Medincell. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Medincell’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Medincell’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Medincell’s growth potential.
Medincell Revenue, EBIT and net profit per share
| Date | Medincell Revenue | Medincell EBIT | Medincell Net Income |
|---|---|---|---|
| 2028e | 161.01 M undefined | 95.78 M undefined | 74.85 M undefined |
| 2027e | 109.44 M undefined | 75.17 M undefined | 53.86 M undefined |
| 2026e | 51.56 M undefined | 17.18 M undefined | 8.21 M undefined |
| 2025e | 33.33 M undefined | 1.71 M undefined | -8.57 M undefined |
| 2024 | 9.03 M undefined | -20.84 M undefined | -25.04 M undefined |
| 2023 | 9.89 M undefined | -24.05 M undefined | -32.01 M undefined |
| 2022 | 4.09 M undefined | -23.81 M undefined | -24.81 M undefined |
| 2021 | 8.19 M undefined | -15.58 M undefined | -18.99 M undefined |
| 2020 | 2.85 M undefined | -19.32 M undefined | -23.92 M undefined |
| 2019 | 1.44 M undefined | -15.52 M undefined | -19.69 M undefined |
| 2018 | 6.44 M undefined | -7.38 M undefined | -9.57 M undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2018 | 6.44 M EUR | -7.38 M EUR | -9.57 M EUR |
| 2019 | 1.44 M EUR | -15.52 M EUR | -19.69 M EUR |
| 2020 | 2.85 M EUR | -19.32 M EUR | -23.92 M EUR |
| 2021 | 8.19 M EUR | -15.58 M EUR | -18.99 M EUR |
| 2022 | 4.09 M EUR | -23.81 M EUR | -24.81 M EUR |
| 2023 | 9.89 M EUR | -24.05 M EUR | -32.01 M EUR |
| 2024 | 9.03 M EUR | -20.84 M EUR | -25.04 M EUR |
| 2025e | 33.33 M EUR | 1.71 M EUR | -8.57 M EUR |
| 2026e | 51.56 M EUR | 17.18 M EUR | 8.21 M EUR |
| 2027e | 109.44 M EUR | 75.17 M EUR | 53.86 M EUR |
| 2028e | 161.01 M EUR | 95.78 M EUR | 74.85 M EUR |
Medincell stock margins FR0004065605 · A2N6VA
The Medincell margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Medincell. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Medincell.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Medincell's sales revenue. A higher gross margin percentage indicates that the Medincell retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Medincell's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Medincell's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Medincell's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Medincell. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Medincell's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Medincell Margin History
| Medincell Gross margin | Medincell Profit margin | Medincell EBIT margin | Medincell Profit margin |
|---|---|---|---|
| 2028e | 74.92 % | 59.49 % | 46.49 % |
| 2027e | 74.92 % | 68.68 % | 49.21 % |
| 2026e | 74.92 % | 33.32 % | 15.92 % |
| 2025e | 74.92 % | 5.12 % | -25.71 % |
| 2024 | 74.92 % | -230.78 % | -277.21 % |
| 2023 | 65.28 % | -243.22 % | -323.69 % |
| 2022 | 63.23 % | -582.25 % | -606.5 % |
| 2021 | 82.27 % | -190.28 % | -231.93 % |
| 2020 | 66.02 % | -677.56 % | -838.53 % |
| 2019 | 30.03 % | -1,076.01 % | -1,365.26 % |
| 2018 | 89.5 % | -114.58 % | -148.64 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2018 | 89.5 % | -114.58 % | -148.64 % |
| 2019 | 30.03 % | -1,076.01 % | -1,365.26 % |
| 2020 | 66.02 % | -677.56 % | -838.53 % |
| 2021 | 82.27 % | -190.28 % | -231.93 % |
| 2022 | 63.23 % | -582.25 % | -606.5 % |
| 2023 | 65.28 % | -243.22 % | -323.69 % |
| 2024 | 74.92 % | -230.78 % | -277.21 % |
| 2025e | 74.92 % | 5.12 % | -25.71 % |
| 2026e | 74.92 % | 33.32 % | 15.92 % |
| 2027e | 74.92 % | 68.68 % | 49.21 % |
| 2028e | 74.92 % | 59.49 % | 46.49 % |
Medincell Aktienanalyse
What does Medincell do?
Medincell SA is a leading biotechnology company based in Montpellier, France, specializing in the development and manufacturing of innovative drugs based on its proprietary Intellisome® technology platform. The company was founded in 1999 by Dr. Christophe Douat and has since built an impressive portfolio of products and services. Medincell's business model is based on the development and manufacturing of extended-release drugs through the integration of drugs into the Intellisome® technology platform. This is a novel concept based on the use of polymers that are capable of controlling and slowing down the release of drugs. This allows medications to be administered in a specific dosage and duration, providing greater effectiveness and tolerability for the patient. Medincell has several business areas, including the development of drugs for the treatment of central nervous system (CNS) disorders, including schizophrenia, depression, and chronic pain. The company is also working on the development of drugs for the treatment of infectious diseases and cancer, as well as the development of new technologies for drug manufacturing. Medincell's products include a range of drugs, including Long-Acting Risperidone (a depot preparation for the treatment of schizophrenia), Long-Acting Cabergoline (for the treatment of Parkinson's), and Long-Acting Naltrexone (for the treatment of alcohol and drug addiction). The company also has partnerships with other pharmaceutical companies such as Pierre Fabre, Sanofi, Janssen, and Pfizer for the development of products based on its Intellisome® technology platform. Another important area of Medincell is its service for drug development based on the Intellisome® technology platform. The company offers customers comprehensive support in the development, manufacturing, and approval of extended-release drugs. Customers can choose from a wide range of services, ranging from the identification of active ingredients to the implementation of clinical trials. Overall, Medincell has achieved impressive success in the launch of its products and services based on the Intellisome® technology platform. The company has won several awards for its innovative products and services in the pharmaceutical industry, including the Innovation Award from the European Society of Clinical Microbiology and Infectious Diseases in 2018 and the Excellence in Specialty Pharmaceuticals Award from BioPharm America in 2019. In summary, Medincell SA is a leading company in the biotechnology industry specializing in the development and manufacturing of extended-release drugs based on its Intellisome® technology platform. With an impressive range of products and services and partnerships with several renowned pharmaceutical companies, the company has a promising future as a key player in the pharmaceutical industry. Medincell ist eines der beliebtesten Unternehmen auf Eulerpool.com.Net Income Details
Understanding Medincell's Profit Margins
The profit margins of Medincell represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Medincell's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.
Year-to-Year Comparison
Evaluating Medincell's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.
Impact on Investments
Medincell's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.
Interpreting Profit Fluctuations
When Medincell’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.
Frequently Asked Questions about Medincell stock
How has the profit developed compared to last year?
The profit has increased by -21.78% compared to last year fallen
What impact do the earnings have on the shareholders?
An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.
How does Medincell publish its earnings?
Medincell publishes its earnings in the form of quarterly or annual reports.
Which financial indicators are included in the quarterly or annual reports?
The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.
Why is it important for investors to know the earnings of Medincell?
The profits of Medincell are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.
How can one learn more about the earnings of Medincell?
You can learn more about the earnings of Medincell by reviewing the quarterly or annual reports or following the company presentations.
How much dividend does Medincell pay?
Over the past 12 months, Medincell paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Medincell is expected to pay a dividend of 0 EUR.
What is the dividend yield of Medincell?
The current dividend yield of Medincell is .
When does Medincell pay dividends?
Medincell pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Medincell?
Medincell paid dividends every year for the past 0 years.
What is the dividend of Medincell?
For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.
In which sector is Medincell located?
Medincell is assigned to the 'Health' sector.
Wann musste ich die Aktien von Medincell kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Medincell from 10/2/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 10/2/2024.
When did Medincell pay the last dividend?
The last dividend was paid out on 10/2/2024.
What was the dividend of Medincell in the year 2023?
In the year 2023, Medincell distributed 0 EUR as dividends.
In which currency does Medincell pay out the dividend?
The dividends of Medincell are distributed in EUR.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The Medincell stock can be added to a savings plan with the following providers: Trade Republic
Andere Kennzahlen von Medincell
Our stock analysis for Medincell Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Medincell Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
